• Bloomberg article reports that sales of classic cars have remained “positively stable” during global pandemic
• Two key acquisitions help firmly establish PRPI’s position in multibillion-dollar classic car market
• CEO notes that PRPI’s acquisition of Worldwide Auctioneers will lead to company’s greater growth

While COVID-19 may have dampened the new-car market, a recent Bloomberg article noted that the global pandemic had little impact on the sales of classic cars (https://ibn.fm/lkWMO). That’s good news for Perpetual Industries (OTC: PRPI), which earlier this year announced two key acquisitions — the Worldwide Group LLC, operating as Worldwide Auctioneers, and AutoGrafic Software System — both aimed at firmly establishing the company’s position in a multibillion-dollar classic car market. “From Bentley to BMW, Polestar to Porsche, new-car sales have slumped in 2020,” Bloomberg reported. “Sales of classic cars, on the other hand, have remained positively stable.” The article quoted Brian Rabold, vice president of valuation services at Hagerty, a company that insures classic and collectible cars, who noted that last year “was a very strange year. There was a lot of appetite to buy cars.” Rabold observed that the proliferation of online platforms from auction houses and startups alike fueled consumer hunger. “A lot of people had more time, they weren’t traveling, they weren’t leaving the house. You could just sit in front of the computer and shop. All of that conspired to make 2020 really strong. . . . In unstable times, car people tend to hang onto their blue-chip cars and get other ones, so there’s a lot of interest that has picked up there.” PRPI reports that the U.S. classic car market has seen steady expansion over recent years, with revenue reaching approximately $12.63 billion in 2020 and forecasted to total an estimated $15.52 billion by 2023, representing a CAGR of more than 7% (https://ibn.fm/Fydhj). Classic car dealers have cornered a significant portion of this market opportunity. With that market potential as a backdrop, Perpetual Industries completed its acquisition of Worldwide Auctioneers in January 2021 (https://ibn.fm/9wa4U). A U.S.-based boutique auction company specializing in the sale and acquisition of classic vintage motorcars at auction around the globe, Worldwide Auctioneers also has a stellar reputation for offering an extensive range of personalized services to collectors, including private sales, appraisal, collection direction and consultancy, estate planning, and asset management. “I am excited to welcome the entire Worldwide team to Perpetual’s umbrella,” said PRPI CEO Brent Bedford. “Their entrepreneurial spirit is a good match with ours, and I am looking forward to achieving greater growth in Perpetual while playing a key role in reaching the future goals of Worldwide.” A few months later, in April, PRPI took another critical step forward with the acquisition of AutoGrafic Software System, a software as a service (SaaS) and social application that utilizes cutting-edge technology to host many aspects of automotive promotion and preservation. AutoGrafic targets global collector car and automotive enthusiasts who want a unique, multifaceted, interactive automotive experience that is focused on a visual-based social community, collection management, social events, auctions, insurance, research, preservation and historical documentation. “This acquisition provides another foundational piece in our quickly expanding blockchain division and, in addition to outstanding software, augments our team with some truly exceptional talent,” said Bedford. “It will also greatly benefit Worldwide Auctioneers, our newly acquired wholly owned subsidiary, by bringing much-needed new technology and innovation to their customers and the collector car industry at large.” Perpetual Industries is an incubator for the development of new and innovative energy-efficient technologies. The company’s mission is to “perpetuate industry” by bringing value-added technologies to market. The company is expanding its expertise and knowledge of energy-efficient technology by developing low-cost, green-energy-powered solutions for a variety of industries while continuing its research, development and commercialization of the XYO Technology in key applications. For more information, visit the company’s website at www.PerpetualIndustries.com. NOTE TO INVESTORS: The latest news and updates relating to PRPI are available in the company’s newsroom at https://ibn.fm/PRPI

• Lexaria just completed dosing for its second human clinical study, HYPER-H21-2
• The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
• The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
• Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
• It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes

Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article.  Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD (https://ibn.fm/4eBs1). The company projects that preliminary results would be available for reporting either in September or earlier. This second human clinical trial involved 16 human volunteers who previously dealt with hypertension or were mildly hypertensive at the time of the study. Each of the 16 participants received three different doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo for a total dose of 450 mg. the study involved a 24-hr continuous ambulatory (portable) monitoring of vitals such as blood pressure and heart rate, while also taking into consideration evaluations of central arterial stiffness, physical activity as well as sleep quality. Lexaria hopes to commence with the third and last human clinical hypertension study of 2021, HYPER-H21-3. It will offer updates in due course. As the company celebrates the progress achieved through this second human clinical trial, Lexaria marked another massive milestone by increasing its market reach in the United States (“US’).  With partnerships with Cannadips, New World CBD, Impact Naturals and Amari, among others, Lexaria’s DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the US (https://ibn.fm/fOYnK). In an official statement from Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, he noted that “Lexaria technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” Lexaria is a global leader in enhancing the overall speed and efficiency of orally-delivered fat-soluble active molecules and drugs. With its drug delivery technology and its advancing intellectual property (“IP”), the company is transforming existing consumer products and medications that may improve their availability and bioavailability. Its flagship technology, DehydraTECH(TM), improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of the fat-soluble active molecules. As of early July 2021, Lexaria had 20 patents falling under 13 different patent families. In July, it got its second patent in Japan titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof.” This became the company’s 21st patent granted to the company and the 17th patent granted to its first patent family. Also, in July, Lexaria received US$3,817,643 from warrant exercises. The company issued the warrants in relation to its January 2021 public underwritten offering. Under this offering, the shares and warrants issued were registered according to a Form S-1 Registration Statement. They were excised into 580,189 shares of voting common stock of the company at an exercise price of US$6.58 per share (https://ibn.fm/IeVUp). Lexaria noted that all proceeds received from the warrant exercises would be used to continue advancing the company’s investigational research program and for general corporate purposes. With these critical milestones achieved so far, Lexaria is confident that its business plan objectives, along with all its operations, are now all set and fully funded, well into the 2022. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Avricore Health signed the first amendment to its supplier distribution agreement between subsidiary HealthTab and Abbott
• The amendment adds to the agreement Abbott’s ID Now(TM) molecular testing device, which will bring in onsite testing and reporting capabilities for SARS-CoV-2 (Covid-19), RSV, Influenza A & B, and Strep
• Avricore also announced its partnership with Ellerca Health, which will see the companies use their respective technologies (Avricore’s HealthTab and Ellerca’s 360Care app) to support patient needs at community pharmacy level

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) recently made several key strides in its quest to become the world’s leader point-of-care technologies within community pharmacy. On July 26, the company announced the signing of the first amendment to its supplier distribution agreement between its wholly owned subsidiary and flagship offering, HealthTab(TM) Inc, and Abbott (NYSE: ABT), the global healthcare company and diagnostics leader, in Canada (https://ibn.fm/5IKuw). Under the original supplier distribution agreement, first signed on May 31 this year (https://ibn.fm/oWz8Y), HealthTab received the mandate to distribute in Canada Abbott’s Afinion(TM) 2 – a small, fast, and multi-assay analyzer providing valuable point-of-care testing to patients – and associated tests for diabetes and heart-disease screening in community pharmacies, including HbA1c testing – also known as A1C. A few days later, Avricore signed the Master Agreement with Canada’s largest pharmacy network, Shoppers Drug Mart, that would enable patients to access its HealthTab platform – an innovative point-of-care blood screening and health-data management platform – integrated with Abbott’s Afinion 2 analyzers. The company has since completed a test rollout of its platform in which over 600 results were reported in the week-and-a-half trial period (https://ibn.fm/DDwar). Following the test rollout, a pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, expressed his excitement at having HealthTab in his store because the platform would demonstrate a new, better way of doing pharmacy practice. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively,” Mohamed Adel Elsabakhawi had said (https://ibn.fm/lcdQ9). In what will surely expand the capabilities of pharmacists like Mohamed in addition to helping detect infections before they spread, the first amendment adds to the distribution agreement Abbott’s ID Now(TM) molecular testing device, which will introduce onsite testing and reporting capabilities for SARS-CoV-2, RSV, Influenza A & B, and Strep. “A missing link today in the response to COVID-19 and general virus outbreak is the ability to get confirmatory testing and reliable, real-time reporting in a low-barrier setting,” said Avricore CEO Hector Bremner. “With ID Now on the HealthTab network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.” Avricore, which expects to add more analyzers and testing capabilities, also signed a partnership agreement with Ellerca Health Corp, a Toronto, Canada-based digital health organization revolutionizing the personal experience and health outcomes of people living with chronic diseases (https://ibn.fm/1EteR). The mutual collaboration on a project-by-project basis will see the companies use Avricore’s HealthTab and Ellerca’s 360Care(TM) to support patients’ needs at the community pharmacy level. The technologies will prioritize early detection, screening, and the consistent management of chronic diseases, like diabetes, as well as support better health outcomes for people living with these conditions. The partnership will, for instance, allow Ellerca’s members to easily access A1C testing at local pharmacies and improve the speed of results. The 360Care is a supportive, app-based digital platform that facilitates self-management of chronic diseases and allows patients to be in control of their own treatment. By working together with patients in this way, the platform lowers the time and cost of reactionary treatments and shifts the focus to preventative care by reducing and eliminating symptoms of chronic conditions. Avricore and Ellerca are looking forward to bringing to community pharmacy enhanced patient services that combine HealthTab’s diagnostics and data-management systems with the ongoing coaching and support of 360Care. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Emaginos is committed to solving two major education problems
• Investing in Emaginos provides an opportunity to do good and do well, says company president
• Company plans to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices

Emaginos, a company raising new capital under provisions of Regulation A of the Securities Act of 1933 (please see website if interested in investing), is seeking $3 million to begin the transformation of the K-12 education system in the United States. Based on the company’s proprietary Discover Learning System (“DLS”), Emaginos offers investors an opportunity to attempt to realize return on their investment while fixing one of the nation’s fundamental problems — its educational system. Emaginos is committed to solving two major problems, according to a recent President’s blog (https://ibn.fm/xhXyg). “The first is fixing . . . the outdated and test-bound K-12 public school system,” writes Emaginos president Allan Jones. “The second is enabling teachers and parents to benefit financially from the transformation – doing good while doing well.” Jones explains what doing good while doing well means: “Doing good refers to behaving altruistically or charitably. Doing well refers to being financially secure,” he writes. “Looking at Maslow’s Hierarchy (https://ibn.fm/UZisi) tells us that instinctually we have to focus on doing well before we can consider doing good. Investing in Emaginos provides an opportunity to do both simultaneously.” In his blog, Jones notes that “you don’t need to be a researcher to be aware that America’s public schools are failing to meet the 21st-century educational needs of our children and, therefore, of our country’s future. The current lack of digital and educational equity inherent in America’s K-12 public education system is a shameful disgrace. The ‘teach-to-the-test’ and related reliance on high-stakes testing is turning off our children and driving dedicated teachers from their chosen profession. At the same time, profiteers and elected officials have realized they can use (or abuse) our schools for their financial or political gain. “Along comes Emaginos,” Jones continues. “Our plan is to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices. Note that we are not seeking to create more charter schools. We are not seeking to take over and operate schools. We are not seeking to eliminate teachers’ unions.” So what is Emaginos’s strategy? Emaginos uses existing facilities, staff, students and faculty, explains Jones. “We provide them a comprehensive transformational suite of services and resources that enable the local schools to become engaging learning environments producing entrepreneurial lifelong self-directed learners. Teachers run the schools.” As far as cost, Emaginos products and services require an initial cost to develop, but once developed, they can be sold many times at very low incremental cost. “The first schools will break even,” Jones explains. “Subsequent schools or districts will provide the same revenue but cost progressively less to transform and support. Any profits will enable Emaginos investors to potentially realize a return on their investments as we continue to improve our products and services and grow the business.” The opportunity to both earn a profit and fix a fundamental problem in the country today is an unusual proposition in the world of investing. Jones’s invitation is simple: “If you are interested in joining us in doing good for our students while possibly realizing a return on investment, go to https://Emaginos.com/reasons-to-invest to learn more.” For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
• Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
• The company is positioned to engage several markets, including digital therapeutics and research

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://ibn.fm/xOXo9). Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of the pharmaceutical-grade product.” Ibogaine is a psychoactive substance that can be found naturally in the roots of the African iboga tree. The company is actively researching ibogaine as a potential treatment for traumatic brain injury and other related conditions. All preliminary data show that the drug may also yield promising results as a treatment for neuropathic pain and migraines. In addition, research also indicates that ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addiction. MINDCURE has filed U.S. provisional patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. Both are currently under assessment to determine the preferred method for further developing the compound (https://ibn.fm/ojpg5). Chief Medical Officer Joel Raskin discussed the natural iboga plant as a precious resource, stating, “Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy. Our company’s research team would also have access to this sustainable drug supply.” MINDCURE is positioned to disrupt several different market spaces through its technology, research, and products, including the digital therapeutics space, which covers health interventions delivered through a smart device to induce a behavioral change in the patient. The company’s leading foray into the digital therapeutics space is iSTRYM, an AI-driven software platform that enables personalized and calculated outcomes in psychedelic therapy. The global digital therapeutics market was valued at $2.88 billion in 2019, but it is expected to reach $13.8 billion by 2027 with a CAGR of 20.5% during the forecast period (https://ibn.fm/793EJ). The global market for drug addiction therapy, where ibogaine can be a potential game changer, was valued at $17.65 billion in 2019 and is expected to grow at a CAGR of 7% during the forecast period, resulting in a value of $31.17 billion by 2027 (https://ibn.fm/oAI5T). For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Brain-Computer Interface (“BCI”) market is expanding rapidly, expected to double to USD 406 billion by 2026
• BCI technology, designed to acquire brain signals, analyze and translate them into commands, is one of key driving forces behind EEG technology growth
• Brain Scientific appears poised to capitalize on this novel technology as its applications expand from medical settings to training, consumer engagement, entertainment, and more

The Brain-Computer Interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. As the provider of EEG technology, Brain Scientific (OTCQB: BRSF) appears well placed to leverage this rapid growth of the industry expected to double in size by 2026 (https://ibn.fm/F5LOs). BCI technology refers to solutions that record the brain signal from the surface of the cortex, using sensors placed over the scalp or signaling devices implanted in the brain. As a promising approach to overcome paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector, BCI can provide opportunities for motor rehabilitation from a number of conditions, including spinal cord injury, traumatic brain injury, and stroke (https://ibn.fm/C9Dom). This powerful technology can even help patients who lost the ability to speak to communicate. A recent study reports the first patient ever to produce whole words via a computer that decodes his brain’s messages through electrodes implanted in his brain (https://ibn.fm/gr3j7). Enabling advances never possible before, the BCI space is expanding rapidly, and EEG is an essential part of that landscape. Recent market research reveals that the BCI market is expected to grow at a 12.4% CAGR over the next five years, reaching $409.3 million by 2026 — more than double compared to $203 million reported in 2020. Main growth drivers include swelling demand from healthcare, entertainment, gaming, communication, and control. Traditionally, EEG-based BCI technology has been geared towards medical applications where it was utilized to help disabled patients to interact with the external world. However, with a shift of focus towards people with normal health, the technology is no longer constrained to medical settings only. For example, training — including athletic, military, and occupational — and fields such as consumer engagement and entertainment are becoming target groups that would likely benefit from using EEG-based BCI systems (https://ibn.fm/oV87E). As the application space for EEG-based BCI solutions expands, Brain Scientific appears poised for rapid growth. With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the Company appears well-placed within the growing brain monitoring space. Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the ground-breaking technology that aim to enable what was inconceivable until recently. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• FingerMotion’s SMS & MMS, TPS, and Big Data divisions generated $6.00 million in revenue for Q1 2022
• The SMS & MMS and TPS businesses’ Q1 2022 revenues increased significantly compared to Q1 2021 figures
• Q1 2022 also marked the second consecutive quarter in which the big data division generated revenue, and a Q/Q increase at that
• FingerMotion is also targeting the accretive rich communications services (“RCS”) segment, with RCS expected to form its fourth division

On July 15, evolving technology company FingerMotion (OTCQX: FNGR) released its Q1 2022 results in which it reported record quarterly revenue of $6.00 million, generated by its SMS & MMS, Telecommunications Products & Services (“TPS”), and Big Data divisions. The SMS & MMS division’s revenue was up 77% or $1.81 million compared to Q1 2021, while the TPS division’s revenue grew by 341% or $1.34 compared to a similar period a year before (https://ibn.fm/S1osq). Q1 2022 also marked the second consecutive quarter of revenue from the Big Data division with reported revenue of $98,715. This figure represented a 198% quarter-over-quarter increase, given that in Q4 2021, the division generated $33,077. “Growth continues to be fueled by an expansion of subscribers in new regions along with larger purchases of SMS from our corporate clientele,” commented FingerMotion CEO Martin Shen. “This is the second consecutive quarter of Big Data revenues, and we expect it to continue and eventually outpace our existing revenue streams.” The Q1 2022 results’ announcement followed on the heels of the June 2 release of the company’s financial results for the fiscal year ended February 28, 2021. Here, FNGR reported that its SMS & MMS business and TPS division posted annual revenue growths of $6.13 million (84%) and $1.39 million (76%), respectively, compared to the previous financial year. The two businesses cumulatively contributed to a record annual revenue of $16.68 million (https://ibn.fm/ml4Fh). FingerMotion anticipates that if the current trajectory defined by the Q1 2022 results continues, its revenue for FY 2022 may exceed $24 million, which would represent a year-over-year jump of over 44%. The projected increase is likely to result from its existing operations, suggesting that the SMS & MMS, TPS, and Big Data businesses will continue soaring throughout the remainder of FY 2022. Meanwhile, FNGR is also targeting another high growth opportunity in rich communication services (“RCS”), expected to form the company’s fourth division. Rich communication services are emerging as a formidable technology enabling users to access various advanced capabilities from their native messaging service without installing a third-party application. Such capabilities include group chat, video calling, file sharing, and even additional features such as the ability to book a restaurant or flight. RCS has revolutionized text-based messaging by eliminating previous constraints that limited it to merely sending short text messages. With RCS, messaging has become a platform (https://ibn.fm/pfZPX). MarketsandMarkets projects that the global RCS market will grow from $5.2 billion in 2020 to $11.7 billion by 2025, representing a CAGR of 17.6% CAGR. The Asia Pacific (“APAC”) region is expected to record the highest growth rate during the forecast period, with China playing a dominant role as a key contributor to the growth. The study credits the region’s increasing populations, advanced SMS systems, expanding retail industry, rise in smartphone usage, and growing mobile payments for being behind the growth (https://ibn.fm/PVlm3). FingerMotion identified the accretive opportunities within the emerging RCS segment and, in March 2020, allocated resources for the R&D of a proprietary RCS platform. “This RCS platform is expected to be a proprietary business messaging platform that enables businesses and brands to communicate and service their customers on 5G infrastructure, delivering better user experience, more efficiently and cost-effectively. This is expected to open up a new marketing channel for the company’s current and prospective business partners,” reads a segment from FingerMotion’s annual report filed with the SEC as form 10-K (https://ibn.fm/Elhme). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Epic stage production features a unique end-of-the-world theme
• Company is curating a theme to create a ground-breaking production
• With more than 30,000 national followers, EpicRaves is on its way to achieving goal of becoming nationally recognized concert production company

Golden Triangle Ventures (OTC: GTVH) is making company history with the announcement of its debut event series: Armageddon (https://ibn.fm/5vKmz). This epic stage production features a unique end-of-the-world theme and is the company’s first-ever offering of this kind. “We will deploy the largest Hennessy Sound Design system Las Vegas has ever seen in history for this amazing event, and we are going to curate a theme to our epic production unlike anything we have ever done in the past,” said GTVH CEO Steffan Dalsgaard. “Most of the headliners on our lineup have never played for this city, and we are so excited to debut our new Armageddon event this September.” The series, slated for Sept. 17, 2021, at the Sahara Event Schedule, is presented by GTVH’s wholly owned subsidiary Lavish Entertainment (dba EpicRaves). The headliner performer for the event is MUST DIE! with Oddprophet making his U.S. debut. Others performing during the event include Au5, BeardThug, DirtySnatcha, Psymbionic and Sky Suite, as well as Drezza, Ethyrial, Mutavore, Meek, Channel 0, Killawolf, Vairix and Dub Sum Damage. Dedicated to producing high-quality bass music events in Vegas, one of the world’s best-known entertainment destinations, EpicRaves enhances its ground-breaking performances with custom stage and sound design, state-of-the-art venues and touring DJs from around the world. The company is focusing on creating a fun, entertaining environment for the electronic dance music (“EDM”) community where fans can freely express themselves and where the quality of the event is paramount. With more than 30,000 national followers, the company is on its way to achieving its goal of becoming a nationally recognized concert production company. Lavish Entertainment is also working to build an immersive virtual reality platform to help monetize its live-streamed concerts and assist its business in expanding into markets outside of Las Vegas. In addition, the company recently unveiled Syndicate Bass Records, its own record label that showcases some of the best bass music artists in the world. Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• NOAA predicts above-average 2021 storm season
• SGTM wholly owned subsidiary provides unparalleled services, including commercial property storm recovery, tree trimming, clean up
• Company’s management team deploys its mobile command center, strategized with national partners to provide much-needed services

The National Oceanic and Atmospheric Administration (“NOAA”) Climate Prediction Center is anticipating an above-normal Atlantic hurricane season in the coming months (https://ibn.fm/GNdk1). NOAA forecasters are predicting a 60% chance of an above-normal season, a 30% chance of a near-normal season, and a 10% chance of a below-normal season. The Sustainable Green Team (OTC: SGTM) and its wholly owned subsidiary National Storm Recovery LLC are experts at dealing with the aftermath of storms, regardless of their severity. “For 2021, a likely range of 13 to 20 named storms (winds of 39 mph or higher), of which six to 10 could become hurricanes (winds of 74 mph or higher), including three to five major hurricanes (category 3, 4 or 5; with winds of 111 mph or higher) is expected,” announced the Climate Prediction Center, noting that the predictions, which cover the hurricane season from June 1 through Nov. 30, come with a 70% confidence rating. “Now is the time for communities along the coastline as well as inland to get prepared for the dangers that hurricanes can bring.” The Sustainable Green Team, through National Storm Recovery, offers the kind of expert support and guidance that communities may be looking for in order to prepare for and clean up after severe storms. For the past four decades, National Storm Recovery has provided unparalleled services, ranging from commercial property storm recovery to tree trimming and clean up (https://ibn.fm/N8aEf). National Storm Recovery is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors. National Storm Recovery and its expert team of providers is committed to do all it takes to ensure properties are safe and that business can continue as usual. In addition to superior storm recovery assistance, the company also offers tree removal, stump grinding, tree care, land clearing and grapple hauling. National Storm Recovery received the Angie’s List Super Service Award in 2018, and the company remains committed to providing superior next-level tree service to all who need it. The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability and based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients. To learn more about Sustainable Green Team Ltd., view the company’s investor presentation at https://ibn.fm/etElq. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Nextech Founder and CEO Evan Gappelberg will present at the OTCQB Venture Virtual Investor Conference, scheduled for August 5, 2021, and later at the Jefferies Software Conference to be held September 14 to 15, 2021
• Earlier this year, Evan presented at a Virtual Investor Conference, wherein he highlighted the company’s plans, some of which it has already implemented
• Thus, during the upcoming conferences, which will bring together companies and investors, attendees can expect to learn more about Nextech, its core business, expectations, and more

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), one of the leaders in the rapidly growing augmented reality (“AR”) industry, recently announced that Founder and CEO Evan Gappelberg will present at two upcoming conferences geared towards bringing companies and investors together. On August 5, 2021, starting from 9.30 AM ET, Evan will present at the OTCQB Venture Virtual Investor Conference. The live and interactive online event organized by Virtual Investor Conferences (“VIC”) and beamed live on VirtualInvestorConferences.com will feature favorite venture companies traded on the OTCQB (https://ibn.fm/jACO2). A premier proprietary investor conference series, VIC provides an interactive forum for publicly traded companies to discuss their businesses and investment stories, in addition to answering questions from investors. As a live, online event under the VIC umbrella, therefore, the OTCQB Venture Virtual Investor Conference will not be an outlier. It will promote interactivity by allowing investors to ask companies questions in real-time. The organizers will also make available an archived webcast of the presentations after the event. Similarly, Evan will present and host 1×1 meetings at the annual Jefferies Software Conference scheduled for September 14 to 15, 2021. Aimed at addressing both near- and long-term investment opportunities, as well as discussing current trends in the United States and beyond, the upcoming event will bring together public and private software companies, leading executives, institutional investors, venture capitalists (“VCs”), and private equity investors. It will feature 1×1/small group meetings, company presentations, fireside chats, and panels (https://ibn.fm/hhmbi). These two presentations will come just a few months after a February 4 precursor (https://ibn.fm/HlFcV) – which was also a VIC event – during which Evan outlined Nextech’s progress up until that point and expectations for 2021, including planned product and technology launches, as well as its revenue forecast. “Before we get started with the presentation, I just want to put a little context into the presentation. In 2019, we generated $6 million in revenue. In 2020, we preannounced our revenue as $20 million, and in 2021, we are estimating $50-$60 million in revenue,” Evan began (https://ibn.fm/zHpiq). He then went on to describe “catalysts” for the company beyond revenue, which mainly revolved around expected technology launches within its AR division. These included a proprietary Ad Network and a live holoportation feature on its AirShow App. Nextech has since launched these two technologies in addition to others, such as LiveX, its digital experience platform (“DXP”) released May 12, and EdTechX, a higher education solution built on Microsoft Azure and available on the LiveX platform. If the earlier VIC presentation is anything to go by, attendees at the two upcoming conferences can expect to gain more insight into Nextech, its expectations for the future, and the progress it will have made up until then. They can also expect to learn more about AR, Nextech’s core business, present and emerging technologies that will support AR, and more. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF